New drug combo aims to fight resistant lung cancer
NCT ID NCT05009836
First seen Jun 12, 2026 · Last updated Jun 24, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether adding savolitinib to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR-mutant, MET-positive non-small cell lung cancer). About 412 participants will receive either the combination or a placebo plus osimertinib. The study measures how long the cancer stays under control and checks for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong General Hospital
Guangzhou, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
savolitinib combined with osimertinib
What this could lead to
If successful, this combination could become a new first-line treatment option for people with a specific type of lung cancer, potentially delaying disease progression.
What could go wrong
This is a phase 3 trial, but results are not yet available. The combination may not improve outcomes over standard care and could cause additional side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.